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Atrial fibrillation (AF) is an emerging epidemic in both high-income and low-income coun-
tries, mainly because of global population aging. Stroke is a major complication of AF, and 
AF-related ischemic stroke is more disabling and more fatal than other types of ischemic 
stroke. However, because of concerns about bleeding complications, particularly intracranial 
hemorrhage, and the limitations of a narrow therapeutic window, warfarin is underused. 
Four large phase III randomized controlled trials in patients with non-valvular AF (RE-LY, 
ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) demonstrated that new oral anticoagu-
lants (NOACs) are superior or non-inferior to warfarin as regards their efficacy in preventing 
ischemic stroke and systemic embolism, and superior to warfarin in terms of intracranial 
hemorrhage. Among AF patients receiving warfarin, Asians compared to non-Asians are at 
higher risk of stroke or systemic embolism and are also more prone to develop major bleed-
ing complications, including intracranial hemorrhage. The extra benefit offered by NOACs 
over warfarin appears to be greater in Asians than in non-Asians. In addition, Asians are less 
compliant, partly because of the frequent use of herbal remedies. Therefore, NOACs com-
pared to warfarin may be safer and more useful in Asians than in non-Asians, especially in 
stroke patients. Although the use of NOACs in AF patients is rapidly increasing, guidelines 
for the insurance reimbursement of NOACs have not been resolved, partly because of insuf-
ficient understanding of the benefit of NOACs and partly because of cost concerns. The 
cost-effectiveness of NOACs has been well demonstrated in the healthcare settings of de-
veloped countries, and its magnitude would vary depending on population characteristics 
as well as treatment cost. Therefore, academic societies and regulatory authorities should 
work together to formulate a scientific healthcare policy that will effectively reduce the 
burden of AF-related stroke in this rapidly aging society. 
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Unmet need for anticoagulation: 
Alternatives to warfarin?
Warfarin is highly effective in reducing stroke risk in patients 
with atrial fibrillation (AF). However, using warfarin is not easy; 
effort is needed to educate patients about drug and dietary in-
teractions, and serial monitoring of the international normaliza-
tion ratio (INR) is required. As a result, poor compliance is a 
big problem in warfarin use. A recent population-based cohort 
study showed that 43% of patients stopped warfarin within 3 
years and 61% within 5 years.1 
In addition, warfarin has a narrow therapeutic threshold, and 
the quality of anticoagulation has a critical influence on its effect. 
In a UK cohort study, warfarin therapy with a time in therapeu-
tic range (TTR) of INR of less than 60% did not significantly 
reduce stroke risk compared to no antithrombotic therapy.2 In a 
post hoc analysis of ACTIVE W (Atrial Fibrillation Clopidogrel 
Trial With Irbesartan for Prevention of Vascular Events), in or-
der to ensure the superiority of warfarin over clopidogrel plus 
aspirin the minimum projected TTR threshold was 58%.3 While 
suboptimal doses lead to an increased risk of ischemic stroke, 
overdosing frequently results in hemorrhage that can be fatal. 
Even in the setting of clinical trials, the reported TTRs were 
only about two thirds.4-7 It also has been shown that eight ad-
verse bleeding events are estimated to occur annually for every 
100 patients treated,8 and the underutilization of warfarin is in 
part due to concerns about hemorrhagic risk.
Lastly, the use of warfarin is particularly cumbersome in old 
subjects and in those with stroke. They are more vulnerable to 
bleeding complications that may be related with poor compli-
ance, cognitive impairment, and the frequent presence of co-
morbid diseases that require polypharmacy and invasive proce-
dures. In subjects undergoing invasive treatment, periprocedur-
al management is difficult and carries a high risk for thrombo-
embolism, partly because of the slow onset and offset of action 
(long half-life) of warfarin. 
Therefore, more ideal anticoagulants are required that have a 
wide therapeutic range, a short half-life, and a predictable thera-
peutic effect with fixed or weight-based dosing, without signifi-
cant food or drug interaction.9
Results from major randomized clinical 
trials of new oral anticoagulants
The first clinical study with warfarin was reported in 1955. In 
the meantime, several warfarin alternatives have been tested but 
failed to show benefits because of serious adverse effects, i.e., 
excessive bleeding with idraparinux10 or hepatic dysfunction 
with ximelagatran.11 New oral anticoagulants (NOACs) (dabig-
atran, apixaban, rivaroxaban, and edoxaban) were first intro-
duced in 2005, for prophylaxis against venous thromboembo-
lism after total hip or knee replacement surgery, and are now 
Table 1. Current licensed indications for the new oral anticoagulants
New oral anticoagulants (phase III randomized clinical trials)
Dabigatran Rivaroxaban Apixaban Edoxaban
Prevention of stroke or systemic embolism in  
   adults with non-valvular atrial fibrillation
Approved (RE-LY) Approved (ROCKET-AF) Approved (ARISTOTLE,  
AVERROES)
In process (ENGAGE AF  
TIMI-48)
Prevention of deep vein thrombosis in adults  
   who have undergone elective hip/knee  
   replacement surgery
Approved (REMODEL,  
RE-NOVATE, RE-MOBILIZE, 
RE-NOVATE II)
Approved (RECORD1,  
RECORD2, RECORD3,  
RECORD4)
Approved (ADVANCE-1,  
ADVANCE-2,  
 ADVANCE-3)
In process  
(STARS E3/J-4/J-5)
Acute treatment and prevention of recurrence  
   of deep vein thrombus and pulmonary  
   embolism in adults
Approved (RE-COVER-I, II, 
RE-MEDY, RE-SONATE)
Approved (EINSTEIN-DVT, 
EINSTEIN-PE, 
EINSTEIN-EXT)
In Process (AMPLIFY, 
AMPLIFY-EXT)
In process  
(HOKUSAI-VTE)
Prevention of atherothrombotic events following  
   acute coronary syndrome
Approved in EU (ATLAS ACS 
2-TIMI 51)
RE-LY, Randomized evaluation of long-term anticoagulant therapy (NCT00262600); ROCKET-AF, Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin 
K antagonism for prevention of stroke and embolism trial in atrial fibrillation (NCT00403767); ARISTOTLE, Apixaban for reduction in stroke and other thromboembolic events in 
atrial fibrillation (NCT00412984); AVERROES, Apixaban vs. aspirin in patients with atrial fibrillation and previous stroke or transient ischemic attack (NCT00496769); ENGAGE 
AF TIMI-48, Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (NCT00781391); REMODEL, Oral dabiga-
tran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement (NCT00168805); RE-NOVATE, Dabigatran etexilate vs. 
enoxaparin for prevention of venous thromboembolism after total hip replacement (NCT00168818); RE-MOBILIZE, Oral thrombin inhibitor dabigatran etexilate vs. North Ameri-
can enoxaparin regimen for prevention of venous thromboembolism after knee-replacement surgery (NCT00152971); RECORD, REgulation of Coagulation in ORthopedic Sur-
gery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (NCT00329628, NCT00332020, NCT00361894, NCT00362232); ADVANCE, Apixaban Dose Orally vs. ANti-
Coagulation with Enoxaparin (NCT00371683, NCT00452530, NCT00423319); RE-COVER, Dabigatran vs. warfarin in the treatment of acute venous thromboembolism (NCT00 
291330, NCT00680186); RE-MEDY, Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism (NCT00329238); RE-SONATE, Dabigatran vs. place-
bo for extended maintenance therapy of venous thromboembolism (NCT00558259); EINSTEIN, Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic 
deep vein thrombosis or pulmonary embolism (NCT00439725, NCT00439777, NCT00439725); AMPLIFY, Apixaban after the initial Management of PuLmonary embolIsm and 
deep vein thrombosis with First-line therapY (NCT00643201, NCT00633893); ATLAS ACS 2-TIMI, Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or 
without thienopyridine therapy in Subjects with Acute Coronary Syndrome (NCT00402597).
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used to prevent and treat deep vein thrombosis and pulmonary 
embolism (Table 1).12 
More recently, four large phase III randomized controlled tri-
als of NOACs (RE-LY, ROCKET-AF, ARISTOTLE, and EN-
GAGE-AF-TIMI 48) have been completed in patients with non-
valvular AF.4-7 Overall, NOACs were superior or non-inferior to 
warfarin in the prevention of ischemic stroke and systemic em-
bolism, but superior to warfarin in reducing hemorrhagic stroke.4-7 
NOACs may be more beneficial among patients with AF-relat-
ed stroke or transient ischemic attack (TIA); a recent meta-anal-
ysis showed that NOACs significantly reduced stroke or sys-
temic embolism, as well as hemorrhagic stroke or major bleed-
ing, in patients with AF and previous stroke or TIA.13 The rela-
tive risk reduction and the number needed to treat with NO-
ACs vs. warfarin to reduce stroke/systemic embolism were esti-
mated to be 14% and 134 patients; for avoiding hemorrhagic 
stroke the respective values were 57.9% and 139 patients.13 Evi-
dence from these trials forms the basis for national and interna-
tional guidelines for the management of patients with non-val-
vular AF in clinical practice. Although aspirin was preferred in 
patients with a low-risk of stroke, new and safer anticoagulants 
may lead to lowering of the threshold for anticoagulation.14 
The selection of antithrombotic agent (warfarin vs. NOACs) 
should be individualized on the basis of risk factors, cost, tolera-
bility, patient preference, potential for drug interactions, and 
other clinical characteristics such as renal function and TTR.15 
It would be unnecessary to switch from warfarin to NOACs in 
patients who already achieve stable and good INR control with 
warfarin. Good anticoagulation control (TTR > 70%) is associ-
ated with the best efficacy and safety of warfarin,2 and the re-
cent meta-analysis of the four phase III NOACs trials showed 
that there was a greater relative reduction in major bleeding with 
NOACs when the TTR was less than 66% than when it was 
greater.16
Viewing NOACs from Asian perspectives 
The use of NOACs may be more beneficial for Asian patients. 
First of all, it appears that Asians more often have cerebral small 
vessel disease, which is prone to bleeding. It has been shown 
that hemorrhagic stroke (intracerebral or subarachnoid hemor-
rhage), which accounts for 15% to 20% of strokes in whites,17 is 
more frequent among Asians.18 Death from hemorrhagic stroke 
is also much more common in Asians.19 The prevalence of cere-
bral microbleeds, which increase the risk of intracerebral hem-
orrhage on anticoagulation, also appears to be higher in Asian 
than in white population.20 The ethnic differences in bleeding-
prone small artery disease are in part related with the high prev-
alence of uncontrolled hypertension or hypocholesterolemia in 
this region.21 Ethnic differences in the salt sensitivity of intracra-
nial hemorrhage (ICH) have also been addressed.22 Whatever 
the reason, these small artery diseases predispose patients to ce-
rebral bleeding when they are given antithrombotics; the pres-
ence of cerebral small artery diseases, such as lacunar infarcts, 
white matter ischemia or microbleeds, increases the risk of ICH 
in patients receiving antiplatelet agents23 or anticoagulants.24,25 
A recent study showed a high prevalence of warfarin-associated 
ICH in Asians, even if the INR levels were comparable; the haz-
ard ratio for ICH was 4.06 for Asians, and 2 for Hispanics and 
blacks compared to whites.26 Considering that NOACs have a 
lower bleeding risk than warfarin, the benefit of NOACs may 
be greater in Asian patients.
Second, Asians generally favor complementary treatment, 
such as herbal medication and healthy food. According to a 
study from Korea, 40% of patients who were initially treated in 
a large tertiary hospital tried additional herbal treatment after 
discharge.27 This is in strong contrast to a report from Canada, 
where patients with cerebrovascular diseases rarely used alter-
native medicine.28 A study from Hong Kong found that 26% of 
patients taking warfarin had ingested herbal remedies.29 This 
behavior probably results in significant warfarin-drug/food in-
teraction, poor INR control, and may at least in part explain the 
lower TTR achievement in Asian (mean 54.5%) than in non-
Asian (66.2%) patients in the RE-LY trial.30,31 As Asians more 
often had a lower (rather than higher) INR level, another expla-
nation would be that Asian physicians tend to target a relatively 
low INR because of the fear of bleeding complications. Indeed, 
Japanese guidelines recommend a target INR of 1.6-2.6 for Jap-
anese people.32 Whatever the reason, INR control is relatively 
poor in Asia, which also supports the notion that NOACs may 
be more suitable for Asians. 
Finally, there has been evidence that population frequencies 
of genetic polymorphisms related with warfarin metabolism and 
action (e.g., CYP2C9 and VKORC1) differ according to ethnic-
ities.33-35 Apart from being linked to ethnic variations in the re-
quired warfarin dose, these differences may also partly explain 
the poor INR control and the higher risk of ICH among Asians.
Recent studies report that NOACs may be particularly valu-
able in Asians compared to non-Asians.31,36,37 The RE-LY inves-
tigators reported that, among patients treated with warfarin, Asi-
ans (vs. non-Asians) had higher rates of ischemic stroke (by 2.1-
fold) as well as hemorrhagic stroke (by 2.4-fold), despite similar 
blood pressure, younger age, and relatively lower INR values. 
The magnitude of the benefit from dabigatran in the prevention 
of ischemic stroke and hemorrhagic was greater in Asians than 
in non-Asians.31 More recently, Chiang and colleagues reported 
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a post-hoc analysis of the Asian population included in the RE-
LY and ARISOTLE trials, which showed that, compared to 
non-Asians, Asians had a lower number needed to treat with 
NOACs vs. warfarin to reduce stroke/systemic embolism, and 
a higher number needed to treat to avoid hemorrhagic compli-
cations, favoring their use in Asians in terms of both efficacy 
and safety.38
Using NOACs in Asian stroke patients 
may be cost-effective 
Cost-effectiveness analyses showed that NOACs are cost-effec-
tive relative to warfarin for stroke prevention in patients with AF 
and stroke/TIA.39-41 Cost-effectiveness is associated with the cost 
of the drug, care costs, the loss of productivity due to disability 
following recurrent disease, individual patient risk for thrombo-
embolism and bleeding, and the quality of anticoagulation con-
trol (i.e., TTR) which in turn is related to compliance, warfarin 
pharmacogenomics, and accessibility for regular INR tests. 
We suggest that NOACs may be particularly cost-effective in 
Asian stroke patients for the following reasons. First, the risk of 
both recurrent thromboembolism and bleeding is higher in 
stroke patients than in patients without stroke. Moreover, as 
discussed above, Asians are at higher risk of warfarin-related 
ICH, a devastating condition, than Caucasians. Second, patients 
with AF-related stroke have a poorer control of INR than those 
without stroke, probably because of more severe neurological 
disability and a lack of access to frequent INR monitoring. It 
has been shown that most (> 70%) AF-related stroke patients 
have lobar or territorial infarcts,42 and poor anticoagulation con-
trol is associated with the size of brain infarcts (Figure 1).43 
Thus, Asian stroke patients more often face problems in us-
ing warfarin: difficulty in maintaining INR and frequent bleed-
ing complications. In this regard, NOACs appear to be particu-
larly cost-effective for Asian stroke patients. However, NOACs 
are expensive drugs and studies focusing on the cost-effective-
ness of NOACs in Asian stroke patients are unavailable. Never-
theless, given the considerations so far discussed, we propose 
that the reimbursement policy for the use of NOACs should be 
more generous for Asian stroke patients.
Viewing reimbursement guidelines for 
NOACs from strokologists’ perspective
The guidelines for the reimbursement of NOACs are sum-
marized in Table 2. In Japan, Taiwan, Norway, Switzerland, Ice-
land, and the United Arab Emirates, there is no restriction as 
long as NOACs are prescribed on-label. The reimbursement 
guidelines for NOACs in some European countries, including 
the UK, France, and Germany, are based only on the CHADS2 
score (≥ 1). Other European countries and Canada include 
both CHADS2 score and the quality of anticoagulation control. 
For example, the provincial reimbursement guideline for NO-
ACs in Canada includes (a) unable to tolerate warfarin, (b) INRs 
not well controlled on warfarin, or (c) unable to have INRs test-
ed regularly, in patients with a CHADS2 score of ≥ 2. 
The guidelines for the reimbursement of NOACs in Korea 
are similar to those of Canada, but the accessibility (ability to 
have INR tested regularly) is not considered. The criteria for 
‘inadequate anticoagulation’ appear to be too strict, especially 
during the maintenance period (Table 3). As a result, it is diffi-
Figure 1. The relationship between stroke severity and the quality of antico-
agulation control. (A) Most strokes related to atrial fibrillation are large cortical 
infarcts, especially among patients who were inadequately anticoagulated. (B) 
Patients with more severe neurological deficits had worse quality of anticoag-
ulation. The time in therapeutic range of the international normalized ratio (INR) 
was negatively correlated with the baseline neurological deficits (r= -0.262, 
P= 0.010). Figure modified from Oh et al.42 NIHSS= National Institutes of Health 
Stroke Scale.
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Table 2. Reimbursement of new oral anticoagulants
Category Country No. of countries
Full reimbursement Japan, Norway, Switzerland, Taiwan, Iceland, United Arab Emirates   6
CHADS2 score ≥ 1 United Kingdom, Bulgaria, France, Germany, Ireland, Luxembourg, Netherlands, Belgium   8
CHADS2 score ≥ 1 and poor control with warfarin Scotland, Finland, Slovenia, Czech republic, Slovakia, Austria, Denmark, Sweden, Spain, Australia 11
CHADS2 score ≥ 2 and poor control with warfarin Canada, Korea, Israel   3
CHADS2 score > 3 and HAS-BLED > 3 Italy   1
Non-reimbursement U.S., Albania, Bosnia and Herzegovina, Croatia, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, 
Macedonia, Malaysia, Malta, New Zealand, Poland, Portugal, Singapore, Turkey 
18
Table 3. The reimbursement guideline for new oral anticoagulants in Korea
Inclusion
Patients with non-valvular atrial fibrillation
AND
High risk patients, defined as those with
History of thromboembolism (stroke, transient ischemic attack, systemic embolism), OR 
At least two of the followings 
Age ≥ 75 years, heart failure, hypertension, diabetes, and LVEF < 35% or fractional shortening < 25%
AND
Anticoagulation with warfarin is contraindicated, OR
Hypersensitivity to warfarin, OR
Inadequate anticoagulation, defined as follows:
1. During the initiation period
Reimbursement will be accepted when the following are detected even once: 
INR> 3 after 5 days of 1 mg dose 
INR< 2 after 5 days of 10 mg dose 
Reimbursement will be accepted when INR > 3.5 is detected over 3 times within 1 week
2. During the maintenance period
Five INR tests are required during a 6-month period.
If an INR outside the target range (2-3) is detected on more than 40% of occasions in recent 6-month period (> 2 of the 5 INR tests),
Evidence should be provided of efforts to maintain INR within the target range, such as dose escalation (history of prescribed warfarin dose), or the physician’s opinion  
   should be provided when dose escalation is impossible.
3. Other causes 
The patient experienced major bleeding during warfarin medication (requiring transfusion more than two pints)
cult to prescribe NOACs to stroke patients with severe disabili-
ty, or those who live in remote areas (e.g., on an island) and are 
thus unable to test INR regularly. The guideline also recom-
mends a frequent change of warfarin dose (at least 5 times dur-
ing 6 months) to monitor INR. This is in conflict with a ran-
domized study comparing TTR between warfarin dose assess-
ment every 4 weeks vs. every 12 weeks, which showed that fre-
quent dose changes to monitor INR are unnecessary and result 
in temporary fluctuation of the INR.44 Moreover, the guidelines 
state that reimbursement can be allowed if patients have a major 
bleeding complication during warfarin treatment. From the 
strokologist’s point of view this does not make sense, because 
warfarin-associated ICH is frequently fatal. 
We understand that the strict guidelines can be attributed to 
the high cost of NOACs, which may adversely affects the health 
budget, but we would suggest that the guidelines be more gen-
erous to Asian stroke patients, who are particularly vulnerable 
to the adverse effects of warfarin. We suggest that this approach 
may be more cost-effective than not using NOACs, because re-
current ischemic stroke or ICH will be very costly in this rapidly 
aging society. As discussed above, cost-effectiveness studies on 
Asian stroke patients are unavailable and should be performed 
in the future to answer this question.
Conclusions
AF is an emerging global epidemic in both high-income and 
low-income countries. Recently, the use of NOACs in AF pa-
tients has been rapidly increasing, but the cost of NOACs is un-
affordable in low-income to middle-income countries. Conse-
quently, the reimbursement guidelines for NOACs tend to be 
over-restrictive. However, the cost-effectiveness of NOACs will 
depend on the characteristics of patients as well as therapy pricing. 
Asian countries are facing population aging at a pace that is 
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unprecedented and an increasing burden of stroke, particularly 
AF-related stroke. AF-related stroke is more disabling and more 
fatal than other stroke subtypes, and is expected to increase sub-
stantially in the decades to come (Figure 2). Compared to Cau-
casians, Asians more often develop hemorrhagic stroke and war-
farin-related ICH, as well as any stroke in the case of patients 
with AF, and the benefit with NOACs vs. warfarin for prevent-
ing stroke and reducing anticoagulation-related ICH would be 
particularly high in Asians. Nevertheless, the current reimburse-
ment guidelines are in general suboptimal. We suggest that 
guidelines for using NOACs should be more generous for 
Asian stroke patients.
In addition, as NOACs are expensive, continuous efforts should 
be made by healthcare providers and governors to find the ideal 
candidate for NOACs (most cost-effective group); this includes 
research to find genetic or clinical factors that predict the quali-
ty of anticoagulation control.45,46 Close communication is need-
ed to arrive at a consensus decision regarding the coverage guide-
line for those patients who need NOACs, and to reduce the ev-
er-increasing burden of AF-related stroke. 
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